Adenium Biotech Aps

Adenium Biotech (Copenhagen, Denmark)
 is an early-stage biopharmaceutical company addressing the huge unmet medical need for novel antibiotics for the treatment of Gram-negative bacterial infections acquired at hospitals. The pre-clinical lead program Arenicin is functioning by a completely novel and dual mode of action with extremely low spontaneous mutational frequency. The program is a spin-out from Novozymes, and the pre-clinical pipeline is based on a solid foundation of world-class peptide research.
Andreas Segerros


Mobile: +45 53 50 30 38
Email Click here to contact